Co-administration of Shingles and RSV Vaccines Produces …
WEB1 day ago · GSK plc recently announced topline Phase 3 clinical trial data for a combination regimen of two of its vaccines: the RSV vaccine Arexvy and Shingrix, a market-leading shingles shot. While GSK did not provide specific clinical trial (NCT05966090) data in its September 18, 2024 announcement, the company did confirm that co-administering Arexvy with Shingrix resulted in a “non-inferior immune ...
GSK Announces Positive Topline Data on Co-Administration
WEB3 days ago · Shingles is caused by the reactivation of the varicella-zoster virus (VZV), the same virus that causes chickenpox. 11 By age 50, VZV is present in most adults 12 and may reactivate with advancing ...
GSK Announces Positive Topline Data on Co-Administration of
WEB2 days ago · 530 participants were randomized 1:1 to receive either GSK’s Recombinant Zoster Virus vaccine first dose and GSK’s Respiratory Syncytial Virus, Adjuvanted at visit one (Co-ad), or GSK’s Recombinant Zoster Virus vaccine first dose alone at visit one (Control). ... BioSpace is the digital hub for life science news and jobs. We provide ...
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
WEB3 days ago · Resize. By Robb M. Stewart. GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and ...
New long-term data show SHINGRIX continues to provide high ... - GSK
WEBApr 17, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive data from the ZOSTER-049 long-term follow-up phase III trial which followed participants for up to approximately 11 years following initial vaccination with SHINGRIX (Recombinant Zoster Vaccine or RZV).
New data show Shingrix can provide at least 10 years of ... - GSK
WEBOct 19, 2022 · The Recombinant Zoster Vaccine (RZV) is the first approved shingles vaccine to combine a non-live antigen with GSK’s adjuvant and may help overcome the natural age-related decline in immunity that contributes to the challenge of protecting adults aged 50 years and above from this disease.
New Shingrix data demonstrate 100% vaccine efficacy in the ... - GSK
WEBAug 23, 2023 · GSK plc (LSE/NYSE: GSK) today announced positive results from the first-ever efficacy trial of Shingrix (Recombinant Zoster Vaccine or RZV) in China. These results come from the post-license phase IV trial (ZOSTER-076), which evaluated the efficacy and safety of RZV in preventing shingles in adults aged 50 and over.
Shingrix approved in the US for prevention of shingles in adults ... - GSK
WEBGlaxoSmithKline plc [LSE/NYSE: GSK] today announced that the US Food and Drug Administration (FDA) has approved Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults aged 50 years and older.
GSK's RSV vaccine meets main goal when co-administered with shingles …
WEB2 days ago · British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years ...
GSK Builds Combo Case for RSV, Shingles Shots With Phase III Data
WEB1 day ago · GSK on Wednesday unveiled promising topline Phase III data for a combo regimen of its RSV vaccine Arexvy and shingles shot Shingrix, touting a comparable immunogenicity profile to the individual vaccines. The company did not provide specific data in its announcement, only noting that co-administering Arexvy …
Skip to content